Prognostic biomarker discovery based on proteome landscape of Chinese lung adenocarcinoma

• Published in: Clinical proteomics Vol. 21; no. 1; p. 2
• Main Authors: Huang, Yuqi, Ma, Sheng, Xu, Jun-Yu, Qian, Kun, Wang, Yaru, Zhang, Yi, Tan, Minjia, Xiao, Ting
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 05.01.2024; BioMed Central
• Subjects: Adenocarcinoma; Biomarkers; Biosynthesis; Cancer therapies; Care and treatment; Cell cycle; Cell growth; Clinical medicine; Datasets; Development and progression; Genetic screening; Genomes; Genomics; Health aspects; Lung cancer; Lung diseases; Medical prognosis; Mitophagy; Mortality; Mutation; Pneumothorax; Principal components analysis; Proteins; Proteomes; Proteomics; Respiratory agents; Risk assessment; Tumors; United States > US; Proteome; Solid pathological subtype; Benign lung disease cases; Lung adenocarcinoma; Prognostic biomarker
• ISSN: 1542-6416; 1559-0275
• DOI: 10.1186/s12014-023-09449-2

Despite recent innovations in imaging and genomic screening promotes advance in diagnosis and treatment of lung adenocarcinoma (LUAD), there remains high mortality of LUAD and insufficient understanding of LUAD biology. Our previous study performed an integrative multi-omic analysis of LUAD, filling the gap between genomic alterations and their biological proteome effects. However, more detailed molecular characterization and biomarker resources at proteome level still need to be uncovered. In this study, a quantitative proteomic experiment of patient-derived benign lung disease samples was carried out. After that, we integrated the proteomic data with previous dataset of 103 paired LUAD samples. We depicted the proteomic differences between non-cancerous and tumor samples and among diverse pathological subtypes. We also found that up-regulated mitophagy was a significant characteristic of early-stage LUAD. Additionally, our integrative analysis filtered out 75 potential prognostic biomarkers and validated two of them in an independent LUAD serum cohort. This study provided insights for improved understanding proteome abnormalities of LUAD and the novel prognostic biomarker discovery offered an opportunity for LUAD precise management.